Parametric Portfolio Associates’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $5.72M | Sell |
227,160
-22,597
| -9% | -$578K | ﹤0.01% | 1757 |
|
|
2021
Q4 | $6.89M | Sell |
249,757
-25,765
| -9% | -$746K | ﹤0.01% | 1643 |
|
|
2021
Q3 | $8.9M | Sell |
275,522
-110,620
| -29% | -$3.67M | 0.01% | 1443 |
|
|
2021
Q2 | $11.8M | Buy |
386,142
+10,955
| +3% | +$317K | 0.01% | 1262 |
|
|
2021
Q1 | $11.4M | Buy |
375,187
+44,944
| +14% | +$1.28M | 0.01% | 1557 |
|
|
2020
Q4 | $6.53M | Buy |
330,243
+103,618
| +46% | +$1.67M | ﹤0.01% | 1896 |
|
|
2020
Q3 | $2.96M | Buy |
226,625
+113,182
| +100% | +$1.43M | ﹤0.01% | 2257 |
|
|
2020
Q2 | $1.29M | Sell |
113,443
-10,115
| -8% | -$144K | ﹤0.01% | 2777 |
|
|
2020
Q1 | $1.77M | Sell |
123,558
-79,603
| -39% | -$1.68M | ﹤0.01% | 2461 |
|
|
2019
Q4 | $5.53M | Sell |
203,161
-60,949
| -23% | -$1.68M | ﹤0.01% | 1988 |
|
|
2019
Q3 | $7.56M | Sell |
264,110
-19,841
| -7% | -$578K | 0.01% | 1684 |
|
|
2019
Q2 | $7.89M | Sell |
283,951
-93,325
| -25% | -$2.64M | 0.01% | 1649 |
|
|
2019
Q1 | $12.5M | Sell |
377,276
-60,827
| -14% | -$1.85M | 0.01% | 1263 |
|
|
2018
Q4 | $12.7M | Buy |
438,103
+100,722
| +30% | +$3.62M | 0.01% | 1141 |
|
|
2018
Q3 | $15.5M | Sell |
337,381
-1,811
| -0.5% | -$80.5K | 0.01% | 1085 |
|
|
2018
Q2 | $12.7M | Sell |
339,192
-289
| -0.1% | -$9.76K | 0.01% | 1170 |
|
|
2018
Q1 | $10M | Sell |
339,481
-39,800
| -10% | -$1.35M | 0.01% | 1331 |
|
|
2017
Q4 | $13M | Buy |
379,281
+25,608
| +7% | +$864K | 0.01% | 1097 |
|
|
2017
Q3 | $12.8M | Buy |
353,673
+17,439
| +5% | +$497K | 0.01% | 1040 |
|
|
2017
Q2 | $8.69M | Buy |
336,234
+81,611
| +32% | +$1.73M | 0.01% | 1296 |
|
|
2017
Q1 | $4.89M | Buy |
254,623
+141,993
| +126% | +$2.52M | 0.01% | 1776 |
|
|
2016
Q4 | $1.88M | Sell |
112,630
-10,419
| -8% | -$189K | ﹤0.01% | 2412 |
|
|
2016
Q3 | $2.53M | Sell |
123,049
-483
| -0.4% | -$12.3K | ﹤0.01% | 2182 |
|
|
2016
Q2 | $3.78M | Sell |
123,532
-42,895
| -26% | -$1.49M | 0.01% | 1795 |
|
|
2016
Q1 | $6.23M | Buy |
166,427
+63,150
| +61% | +$2.38M | 0.01% | 1339 |
|
|
2015
Q4 | $4.46M | Buy |
103,277
+16,966
| +20% | +$717K | 0.01% | 1484 |
|
|
2015
Q3 | $3.23M | Buy |
86,311
+44,050
| +104% | +$1.56M | 0.01% | 1469 |
|
|
2015
Q2 | $1.44M | Sell |
42,261
-6,030
| -12% | -$205K | ﹤0.01% | 2512 |
|
|
2015
Q1 | $1.71M | Buy |
48,291
+1,273
| +3% | +$45.6K | ﹤0.01% | 2375 |
|
|
2014
Q4 | $1.6M | Buy |
47,018
+3,800
| +9% | +$135K | ﹤0.01% | 2381 |
|
|
2014
Q3 | $1.67M | Sell |
43,218
-766
| -2% | -$28.6K | ﹤0.01% | 2247 |
|
|
2014
Q2 | $1.71M | Buy |
43,984
+8,122
| +23% | +$302K | ﹤0.01% | 2234 |
|
|
2014
Q1 | $1.23M | Buy |
35,862
+11,828
| +49% | +$366K | ﹤0.01% | 2504 |
|
|
2013
Q4 | $504K | Sell |
24,034
-32,935
| -58% | -$833K | ﹤0.01% | 3158 |
|
|
2013
Q3 | $1.34M | Sell |
56,969
-16,631
| -23% | -$472K | ﹤0.01% | 2310 |
|
|
2013
Q2 | $1.98M | Buy |
+73,600
| New | +$2.13M | 0.01% | 1825 |
|
Other funds holding MYGN
CCM
Parametric Portfolio Associates's MYGN Position: Q1 2022 in Review
Parametric Portfolio Associates reduced its Myriad Genetics (MYGN) stake by 9% in Q1 2022, selling an estimated $578K and leaving 227,160 shares worth $5.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1757.
Parametric Portfolio Associates first reported a position in MYGN in Q2 2013 and has held it in 36 quarters since. The position peaked at $15.5M in Q3 2018. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.
- Parametric Portfolio Associates held 227,160 shares of Myriad Genetics worth $5.72M as of Q1 2022.
- Parametric Portfolio Associates sold 22,597 Myriad Genetics shares in Q1 2022, an estimated $578K.
- Myriad Genetics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1757 holding.
- Parametric Portfolio Associates first reported a position in Myriad Genetics in Q2 2013 and has held it in 36 quarters since.
- Parametric Portfolio Associates's Myriad Genetics position peaked at $15.5M in Q3 2018.
- 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.
Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.